The role of external beam radiotherapy in the treatment of hepatocellular cancer.

Hepatocellular carcinoma (HCC) is increasing in incidence and mortality. Although the prognosis remains poor, long-term survival has improved from 3% in 1970 to an 18% 5-year survival rate today. This is likely because of the introduction of well tolerated, oral antiviral therapies for hepatitis C. Curative options for patients with HCC are often limited by underlying liver dysfunction/cirrhosis and medical comorbidities. Less than one-third of patients are candidates for surgery, which is the current gold standard for cure. Nonsurgical treatments include embolotherapies, percutaneous ablation, and ablative radiation. Technological advances in radiation delivery in the past several decades now allow for safe and effective ablative doses to the liver. Conformal techniques allow for both dose escalation to target volumes and normal tissue sparing. Multiple retrospective and prospective studies have demonstrated that hypofractionated image-guided radiation therapy, used as monotherapy or in combination with other liver-directed therapies, can provide excellent local control that is cost effective. Therefore, as the HCC treatment paradigm continues to evolve, ablative radiation treatment has moved from a palliative treatment to both a "bridge to transplant" and a definitive treatment.

Duke Scholars

Author Sarah Jo Stephens Radiation Oncology

Author Steven Sok Choi Medicine, Gastroenterology

Author Daniele Marin Radiology, Abdominal Imaging

Author Charles Yoon Kim Radiology, Interventional Radiology

Author Michael Aaron Morse Medicine, Medical Oncology

Author Devon James Godfrey Radiation Oncology

Author Brian Gary Czito Radiation Oncology

Author Christopher G. Willett Radiation Oncology

Author Manisha Palta Radiation Oncology